Back To Schedule
Wednesday, June 21 • 10:30am - 11:45am
#322: Is the Future Bright for Treatment of Neurodegenerative Diseases?

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Session
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-17-544-L04-P; CME 1.25; IACET 1.25; RN 1.25

Despite decades of research, we continue to search for meaningful treatment in neurodegenerative diseases such as Alzheimer's and Parkinson's. This session will focus on the impact of patient associations on the progress of treatment. A case study will be explored.

Learning Objectives

Discuss where we are today and what is the future in treatment of diseases such as Alzheimer's or Parkinson's; Describe the impact the associations have had in improving treatment.


Susan Yule


Recent Approaches and the Future of Neurodegenerative Diseases
Conrad Hawkins

Challenges in Drug Development of Disease Modifying Drugs in Alzheimer's Disease
Laura Gault, MD, PhD

How Patients Can Help Regulators to Bring New Treatments for Neurodegenerative Diseases?
Juan Garcia-Burgos, MD

Industry Perspective
Jamie A. Mullen, MD

avatar for Juan Garcia-Burgos

Juan Garcia-Burgos

Head of Public and Stakeholders Engagement Department, European Medicines Agency, Netherlands
Juan García Burgos is a Qualified Medical Doctor from Autonoma University in Madrid, specialised in urology. Juan worked as a urologist surgeon at the Maranon hospital in Madrid. He joined the European Medicines Agency in 2002 and was responsible for coordinating the preparation... Read More →

Laura Gault

Group Project Leader, AbbVie, Inc.
As a Group Project Leader at AbbVie, Dr. Gault is responsible for the global development program for an anti-tau antibody under evaluation for the treatment of Progressive Supranuclear Palsy and Alzheimer’s Disease. Dr. Gault attended medical school and graduate school at Case Western... Read More →
avatar for Conrad Hawkins

Conrad Hawkins

Associate Consultant, KMR Group Inc.
Conrad Hawkins is an associate consultant of KMR Group, a firm specializing in measuring and improving biopharmaceutical R&D performance, evaluating clinical productivity, clinical trial cycle times and enrollment processes as well as study start-up. His areas of expertise include... Read More →

Jamie Mullen

Global Clinical Leader, AstraZeneca
Dr. Mullen is the Global Clinical Leader for Neuroscience at AstraZeneca. He is responsible for medical leadership of lanabesestat and for emerging neuroscience products. He previously held positions in late-phase neuroscience clinical development and was the medical leader on numerous... Read More →
avatar for Susan Yule

Susan Yule

Senior Global Regulatory Leader, F. Hoffmann-La Roche Ltd.
Susan received her Bachelor of Pharmacy degree in Australia, and has over 20 years of regulatory and management experience in local affiliates, global organisations and regulatory agencies. She joined Genentech in South San Francisco in 2010, as a Regulatory Team Leader for the Neuroscience... Read More →

Wednesday June 21, 2017 10:30am - 11:45am CDT
S504abc McCormick Place 2301 South Martin Luther King Jr. Drive, Gate 4 Chicago, IL 60616
  07: SpecialPops, Session